Relevant Officials of SSE Respond to the Press

21 Nov 2022

Q: Recently, there are social media posts on the listing of certain enterprises on the STAR Market, with attention to their business and revenue involving nucleic acid testing. Do you have any comments on this?

A: We have noticed the relevant reports. We pay close attention to and strictly review the listing applications of enterprises involving nucleic acid testing, especially their sci-tech innovation attributes and sustainable operation capabilities. Following the IPO requirements and review standards of the STAR Market, the SSE has carefully reviewed these enterprises' IPO applications, focusing mainly on their sci-tech innovation attributes, the correlation between their nucleic acid testing business and their main business, the sustainability of their related revenue, and whether they would still meet the IPO requirements after excluding such business revenue. Also, the companies were required to make a risk disclosure. The SSE will continue to earnestly implement the decisions and arrangements of the CPC Central Committee and the State Council and the work requirements of the China Securities Regulatory Commission, stick to the positioning of the STAR Market, strictly uphold the threshold for admission, and prudently process the offering and listing work regarding these enterprises. We welcome comments and suggestions from market participants.